Novavax, Inc (NVAX) concluded trading on Wednesday at a closing price of $8.55, with 4.36 million shares of worth about $37.31 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -47.99% during that period and on January 15, 2025 the price saw a gain of about 0.53%. Currently the company’s common shares owned by public are about 160.15M shares, out of which, 152.99M shares are available for trading.
Stock saw a price change of -20.98% in past 5 days and over the past one month there was a price change of -5.21%. Year-to-date (YTD), NVAX shares are showing a performance of 6.34% which increased to 86.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.53 but also hit the highest price of $23.86 during that period. The average intraday trading volume for Novavax, Inc shares is 5.25 million. The stock is currently trading -3.22% below its 20-day simple moving average (SMA20), while that difference is down -1.67% for SMA50 and it goes to -20.82% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 160.15M outstanding shares and institutions hold larger chunk of about 59.02% of that.
The stock has a current market capitalization of $1.37B and its 3Y-monthly beta is at 2.13. It has posted earnings per share of -$2.26 in the same period. It has Quick Ratio of 0.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 7.24% while standing at 6.63% over the month.
Analysts are in expectations that Novavax, Inc (NVAX) stock would likely to be making an EPS of -0.65 in the current quarter, while forecast for next quarter EPS is -0.49 and it is 0.11 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.85 which is -0.47 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.44 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 76.43% while it is estimated to increase by 109.80% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on July 30, 2024 offering an Underweight rating for the stock and assigned a target price of $8 to it. On May 10, 2024, BofA Securities Upgrade their recommendations, while on August 09, 2023, B. Riley Securities Upgrade their ratings for the stock with a price target of $15. Stock get a Market perform rating from TD Cowen on April 20, 2023.
